DEA insists cold drug is not meth-resistant

by Jim Salter

A cold and allergy decongestant containing what the manufacturer says is the first pseudoephedrine that cannot be used in meth production is now available nationwide.

The Drug Enforcement Administration refuses to allow Zephrex-D to be sold over the counter, saying government chemists were able to manufacture from the product.

Zephrex-D has been sold in Missouri since December and suburban St. Louis company Westport Pharmaceuticals rolled out the product to 15,000 pharmacies nationwide last month.

Westport says the amount of meth that can be made using Zephrex-D is so small that it's impractical for meth-makers. The Missouri Narcotics Officers Association says it hasn't found the product in any meth labs.

Nonetheless, the DEA insisted Tuesday that Zephrex-D must be sold from behind the counter like all other products.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

DEA disagrees with firm's meth-resistant claims

May 29, 2013

The Drug Enforcement Administration says a suburban St. Louis pharmaceutical company is wrong for marketing its pseudoephedrine product to imply methamphetamine cannot be made with it.

DEA demonstrates how to make meth

May 29, 2007

The Drug Enforcement Administration a held methamphetamine making seminar in Denver to demonstrate what its agents keep off the streets.

Recommended for you

FDA to start regulating lab-developed tests

15 hours ago

(AP)—The Food and Drug Administration announced Thursday it will begin regulating laboratory-developed tests, a growing class of medical diagnostics that have never before been subject to federal oversight.

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

User comments